{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T22:20:51Z","timestamp":1771280451482,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T00:00:00Z","timestamp":1699747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T00:00:00Z","timestamp":1699747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>In the phase 3 QUAZAR AML\u2010001 trial (NCT01757535) of patients with acute myeloid leukaemia (AML) in remission following intensive chemotherapy (IC) and ineligible for haematopoietic stem cell transplant (HSCT), oral azacitidine (Oral\u2010AZA) maintenance significantly prolonged overall survival (OS) versus placebo. The impact of subsequent treatment following maintenance has not been evaluated. In this post hoc analysis, OS was estimated for patients who received subsequent AML therapy, and by regimen received (IC or lower\u2010intensity therapy). First subsequent therapy (FST) was administered after treatment discontinuation in 134\/238 Oral\u2010AZA and 173\/234 placebo patients. OS from randomization in patients who received FST after Oral\u2010AZA versus placebo was 17.8 versus 12.9\u2009months (HR: 0.82 [95% CI: 0.64\u20131.04], median follow\u2010up: 56.7\u2009months); OS from FST was similar between arms. Among patients who received injectable hypomethylating agents as FST, median OS was 8.2 versus 4.9\u2009months in the Oral\u2010AZA versus placebo groups (HR: 0.66 [95% CI: 0.41\u20131.06]). Forty\u2010eight patients (16\/238 Oral\u2010AZA, 32\/234 placebo) received HSCT following treatment discontinuation, including six Oral\u2010AZA patients still in first remission; Oral\u2010AZA OS benefit persisted when censoring these patients. Oral\u2010AZA maintenance can prolong AML remission duration without negatively impacting survival outcomes after salvage therapies.<\/jats:p>","DOI":"10.1111\/bjh.19202","type":"journal-article","created":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T20:50:02Z","timestamp":1699822202000},"page":"877-886","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML\u2010001"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"first","affiliation":[{"name":"Department of Leukemia University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-5536","authenticated-orcid":false,"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"Ulm University Hospital  Ulm Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre  Melbourne Australia"},{"name":"The Royal Melbourne Hospital  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital Universitari i Polit\u00e8cnic La Fe  Val\u00e8ncia Spain"},{"name":"CIBERONC Instituto Carlos III  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-6554","authenticated-orcid":false,"given":"Michael","family":"Pfeilst\u00f6cker","sequence":"additional","affiliation":[{"name":"Third Medical Department for Hematology and Oncology Hanusch Hospital  Vienna Austria"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology Medical University of Vienna  Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-8333","authenticated-orcid":false,"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero Universitaria di Bologna, Istituto di Ematologia \u201cL. e A. Ser\u00e0gnoli\u201d  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-2172","authenticated-orcid":false,"given":"Yinzhi","family":"Lai","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kefeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy L.","family":"See","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7953-7625","authenticated-orcid":false,"given":"Daniel Lopes","family":"de Menezes","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0283-2914","authenticated-orcid":false,"given":"Erica","family":"Petrlik","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6872-625X","authenticated-orcid":false,"given":"Thomas","family":"Prebet","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Summit New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3658","authenticated-orcid":false,"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,12]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020224"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620711402533"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000572"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.67"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.027516"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23858"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25162"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25484"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4073"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.153"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879866"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129876"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.11.003"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000223"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135520"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004444"},{"key":"e_1_2_13_18_1","volume-title":"ONUREG\u00ae (azacitidine) [package insert]","year":"2021"},{"key":"e_1_2_13_19_1","volume-title":"ONUREG\u00ae (azacitidine) [summary of product characteristics]","year":"2021"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.326"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016293"},{"key":"e_1_2_13_23_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Myeloid Leukemia V.4. 2023. \u00a9 National Comprehensive Cancer Network Inc.2023. All rights reserved. Accessed [August 30 2023]. To view the most recent and complete version of the guideline go online toNCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.22"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968552.93087.6b"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18783"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013404"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.8"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30210-6"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010022"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00108-3"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.016"},{"key":"e_1_2_13_34_1","unstructured":"ClinicalTrials.gov.Randomised study of oral azacitidine vs placebo maintenance in AML or MDS patients after allo\u2010SCT (AMADEUS) 2022 [NCT04173533] [updated November 3 2022]. Available from:https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04173533"},{"key":"e_1_2_13_35_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Myeloid Leukemia V. 2011. \u00a9 National Comprehensive Cancer Network Inc. 2011. All rights reserved. Accessed [2011]. To view the most recent and complete version of the guideline go online toNCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19202","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.19202","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:19:22Z","timestamp":1771276762000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,12]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/bjh.19202"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19202","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,12]]},"assertion":[{"value":"2023-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}